Rota Lauren M, Wood Teresa L
Department of Pharmacology, Physiology and Neuroscience, New Jersey Medical School and Cancer Center, Rutgers University , Newark, NJ , USA.
Front Endocrinol (Lausanne). 2015 Jun 9;6:92. doi: 10.3389/fendo.2015.00092. eCollection 2015.
The insulin-like growth factor system has long been considered a pathway that promotes cell proliferation, survival, and transformation, and is thus a promoter of tumorigenesis. However, recent failure of clinical trials for IGF-1R inhibitors reveals the need for a better understanding of how this pathway functions in specific tumor subtypes. Ongoing studies are designed to uncover biomarkers and downstream targets to enhance therapeutic strategies. Other approaches in specific tumor models reveal complex interactions between IGF signaling and other tumor initiating pathways. Here, we review relevant background and recent studies suggesting that inhibiting the IGF-1R can amplify Wnt and Notch signaling pathways in a model of triple negative breast cancer.
胰岛素样生长因子系统长期以来一直被认为是一条促进细胞增殖、存活和转化的途径,因此是肿瘤发生的促进因素。然而,最近IGF-1R抑制剂的临床试验失败表明,有必要更好地了解该途径在特定肿瘤亚型中的作用机制。正在进行的研究旨在发现生物标志物和下游靶点,以加强治疗策略。在特定肿瘤模型中的其他研究方法揭示了IGF信号与其他肿瘤起始途径之间的复杂相互作用。在此,我们回顾相关背景和近期研究,这些研究表明在三阴性乳腺癌模型中抑制IGF-1R可放大Wnt和Notch信号通路。